CN107315061B - 一种治疗妇女子宫出血的茜芷中药制剂的检测方法 - Google Patents
一种治疗妇女子宫出血的茜芷中药制剂的检测方法 Download PDFInfo
- Publication number
- CN107315061B CN107315061B CN201710452403.3A CN201710452403A CN107315061B CN 107315061 B CN107315061 B CN 107315061B CN 201710452403 A CN201710452403 A CN 201710452403A CN 107315061 B CN107315061 B CN 107315061B
- Authority
- CN
- China
- Prior art keywords
- solution
- root
- reference substance
- alizarin
- dahurian angelica
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- RGCKGOZRHPZPFP-UHFFFAOYSA-N alizarin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC=C3C(=O)C2=C1 RGCKGOZRHPZPFP-UHFFFAOYSA-N 0.000 title claims abstract description 132
- 238000002360 preparation method Methods 0.000 title claims abstract description 108
- 241000213006 Angelica dahurica Species 0.000 title claims abstract description 80
- 239000002398 materia medica Substances 0.000 title claims abstract description 65
- 230000000740 bleeding effect Effects 0.000 title claims abstract description 12
- 210000004291 uterus Anatomy 0.000 title claims abstract description 12
- 238000001514 detection method Methods 0.000 title claims description 19
- 239000003814 drug Substances 0.000 claims abstract description 53
- 238000000034 method Methods 0.000 claims abstract description 51
- 239000000463 material Substances 0.000 claims abstract description 44
- 241000123069 Ocyurus chrysurus Species 0.000 claims abstract description 40
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 36
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 36
- OLOOJGVNMBJLLR-UHFFFAOYSA-N imperatorin Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OCC=C(C)C OLOOJGVNMBJLLR-UHFFFAOYSA-N 0.000 claims abstract description 33
- XKVWLLRDBHAWBL-UHFFFAOYSA-N imperatorin Natural products CC(=CCOc1c2OCCc2cc3C=CC(=O)Oc13)C XKVWLLRDBHAWBL-UHFFFAOYSA-N 0.000 claims abstract description 33
- 241000125175 Angelica Species 0.000 claims abstract description 28
- 235000001287 Guettarda speciosa Nutrition 0.000 claims abstract description 28
- BBNQQADTFFCFGB-UHFFFAOYSA-N purpurin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC(O)=C3C(=O)C2=C1 BBNQQADTFFCFGB-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229940079593 drug Drugs 0.000 claims abstract description 13
- VLGATXOTCNBWIT-UHFFFAOYSA-N rubimaillin Chemical compound O1C(C)(C)C=CC2=C1C1=CC=CC=C1C(O)=C2C(=O)OC VLGATXOTCNBWIT-UHFFFAOYSA-N 0.000 claims abstract description 13
- 238000012850 discrimination method Methods 0.000 claims abstract description 9
- NEFYSBQJYCICOG-YSEUJXISSA-N cyasterone Chemical compound C[C@H]1OC(=O)[C@@H](C)[C@@H]1C[C@@H](O)[C@](C)(O)[C@@H]1[C@@]2(C)CC[C@@H]3[C@@]4(C)C[C@H](O)[C@H](O)C[C@H]4C(=O)C=C3[C@]2(O)CC1 NEFYSBQJYCICOG-YSEUJXISSA-N 0.000 claims abstract description 8
- SXIFCLOUSXMYIX-UHFFFAOYSA-N cyasterone Natural products CC1OC(=O)C(C)C1CCC(C)(O)C2CCC3(O)C4=CC(=O)C5CC(O)C(O)CC5(C)C4CCC23C SXIFCLOUSXMYIX-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229930189092 Notoginsenoside Natural products 0.000 claims abstract description 3
- 229930182494 ginsenoside Natural products 0.000 claims abstract description 3
- 229940089161 ginsenoside Drugs 0.000 claims abstract description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 189
- 239000000243 solution Substances 0.000 claims description 175
- 239000013558 reference substance Substances 0.000 claims description 137
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 87
- 239000012085 test solution Substances 0.000 claims description 85
- 238000004587 chromatography analysis Methods 0.000 claims description 81
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 73
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 70
- 239000000523 sample Substances 0.000 claims description 61
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 60
- 239000002904 solvent Substances 0.000 claims description 53
- 239000000047 product Substances 0.000 claims description 37
- 239000000741 silica gel Substances 0.000 claims description 37
- 229910002027 silica gel Inorganic materials 0.000 claims description 37
- 238000012360 testing method Methods 0.000 claims description 37
- 239000003208 petroleum Substances 0.000 claims description 35
- 239000000706 filtrate Substances 0.000 claims description 33
- 235000019441 ethanol Nutrition 0.000 claims description 32
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 28
- 238000001914 filtration Methods 0.000 claims description 28
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Substances OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 27
- 239000007788 liquid Substances 0.000 claims description 26
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 24
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 24
- 239000007921 spray Substances 0.000 claims description 21
- 235000008216 herbs Nutrition 0.000 claims description 19
- 239000012488 sample solution Substances 0.000 claims description 19
- 239000000843 powder Substances 0.000 claims description 18
- 239000000377 silicon dioxide Substances 0.000 claims description 18
- 238000011161 development Methods 0.000 claims description 16
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 15
- 229960000583 acetic acid Drugs 0.000 claims description 15
- 239000012362 glacial acetic acid Substances 0.000 claims description 15
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 14
- 238000005259 measurement Methods 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 11
- 238000004809 thin layer chromatography Methods 0.000 claims description 11
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 10
- 229930182490 saponin Natural products 0.000 claims description 10
- 150000007949 saponins Chemical class 0.000 claims description 10
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 9
- 239000011248 coating agent Substances 0.000 claims description 9
- 238000000576 coating method Methods 0.000 claims description 9
- 235000019253 formic acid Nutrition 0.000 claims description 9
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 7
- -1 potassium ferricyanide Chemical compound 0.000 claims description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 239000011259 mixed solution Substances 0.000 claims description 6
- 238000002137 ultrasound extraction Methods 0.000 claims description 6
- 230000005526 G1 to G0 transition Effects 0.000 claims description 5
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 claims description 5
- WVVOBOZHTQJXPB-UHFFFAOYSA-N N-anilino-N-nitronitramide Chemical compound [N+](=O)([O-])N(NC1=CC=CC=C1)[N+](=O)[O-] WVVOBOZHTQJXPB-UHFFFAOYSA-N 0.000 claims description 5
- 239000000945 filler Substances 0.000 claims description 5
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 claims description 5
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 claims description 5
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 claims description 5
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 claims description 5
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 239000000796 flavoring agent Substances 0.000 claims description 4
- 235000019634 flavors Nutrition 0.000 claims description 4
- 239000003205 fragrance Substances 0.000 claims description 4
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 claims description 3
- 239000012046 mixed solvent Substances 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- LFVGISIMTYGQHF-UHFFFAOYSA-N ammonium dihydrogen phosphate Chemical compound [NH4+].OP(O)([O-])=O LFVGISIMTYGQHF-UHFFFAOYSA-N 0.000 claims description 2
- 229910000387 ammonium dihydrogen phosphate Inorganic materials 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 238000004811 liquid chromatography Methods 0.000 claims description 2
- 235000019837 monoammonium phosphate Nutrition 0.000 claims description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 2
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 2
- 239000002023 wood Substances 0.000 claims description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical class [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 claims 1
- 239000002893 slag Substances 0.000 claims 1
- 238000005516 engineering process Methods 0.000 abstract description 8
- 238000003908 quality control method Methods 0.000 abstract description 7
- 238000004458 analytical method Methods 0.000 abstract description 6
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 239000000470 constituent Substances 0.000 abstract description 2
- 230000018109 developmental process Effects 0.000 description 13
- 208000032843 Hemorrhage Diseases 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 6
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 6
- 238000000605 extraction Methods 0.000 description 5
- 239000012467 final product Substances 0.000 description 5
- 238000004611 spectroscopical analysis Methods 0.000 description 5
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 206010046788 Uterine haemorrhage Diseases 0.000 description 3
- AOZUYISQWWJMJC-UHFFFAOYSA-N acetic acid;methanol;hydrate Chemical compound O.OC.CC(O)=O AOZUYISQWWJMJC-UHFFFAOYSA-N 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 229940000406 drug candidate Drugs 0.000 description 3
- KZUYUNXHKAGJQS-UHFFFAOYSA-N ethyl acetate;formic acid;propan-2-one Chemical compound OC=O.CC(C)=O.CCOC(C)=O KZUYUNXHKAGJQS-UHFFFAOYSA-N 0.000 description 3
- 239000003777 experimental drug Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 206010071321 Commotio retinae Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005325 percolation Methods 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 244000303512 Peucedanum ostruthium Species 0.000 description 1
- 235000007155 Peucedanum ostruthium Nutrition 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000012496 blank sample Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- GLMWWMZIEZJGMT-UHFFFAOYSA-N chloroform;formic acid;propan-2-one Chemical compound OC=O.CC(C)=O.ClC(Cl)Cl GLMWWMZIEZJGMT-UHFFFAOYSA-N 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- FBAFATDZDUQKNH-UHFFFAOYSA-M iron chloride Chemical compound [Cl-].[Fe] FBAFATDZDUQKNH-UHFFFAOYSA-M 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/90—Plate chromatography, e.g. thin layer or paper chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710452403.3A CN107315061B (zh) | 2017-06-15 | 2017-06-15 | 一种治疗妇女子宫出血的茜芷中药制剂的检测方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710452403.3A CN107315061B (zh) | 2017-06-15 | 2017-06-15 | 一种治疗妇女子宫出血的茜芷中药制剂的检测方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107315061A CN107315061A (zh) | 2017-11-03 |
CN107315061B true CN107315061B (zh) | 2019-01-25 |
Family
ID=60183624
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710452403.3A Active CN107315061B (zh) | 2017-06-15 | 2017-06-15 | 一种治疗妇女子宫出血的茜芷中药制剂的检测方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107315061B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108445139B (zh) * | 2018-03-26 | 2022-10-21 | 河南省洛正药业有限责任公司 | 一种治疗滑膜炎的中药制剂的鉴别方法 |
CN110376316A (zh) * | 2019-08-28 | 2019-10-25 | 广西国际壮医医院 | 黄皮根药材的质量控制方法 |
CN113791143A (zh) * | 2021-05-07 | 2021-12-14 | 上海凯宝药业股份有限公司 | 一种疏风止痛胶囊中白芷的质量控制方法 |
CN114740131B (zh) * | 2022-04-29 | 2023-10-31 | 甘肃兰药药业有限公司 | 一种茜芷制剂指纹图谱的构建方法及其应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100450501C (zh) * | 2004-03-17 | 2009-01-14 | 天津天士力制药股份有限公司 | 一种治疗心脑血管疾病的中药制剂及其制备方法 |
KR20050088947A (ko) * | 2005-07-30 | 2005-09-07 | 주식회사 오스코텍 | 삼칠근 추출물을 유효성분으로 함유하는 관절염 예방 및치료용 조성물 |
CN102323371B (zh) * | 2011-05-11 | 2014-05-21 | 西安千禾药业有限责任公司 | 一种止血药物致康胶囊的检测方法 |
CN102406732A (zh) * | 2011-11-28 | 2012-04-11 | 卞毓平 | 茜芷胶囊在制备治疗黄褐斑药物中的应用 |
CN103197026A (zh) * | 2013-04-01 | 2013-07-10 | 山西振东开元制药有限公司 | 扶正固本颗粒的质量控制方法 |
-
2017
- 2017-06-15 CN CN201710452403.3A patent/CN107315061B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN107315061A (zh) | 2017-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105259295B (zh) | 参枝苓口服液的质量检测方法 | |
CN107315061B (zh) | 一种治疗妇女子宫出血的茜芷中药制剂的检测方法 | |
CN102590433A (zh) | 一种肝畅制剂的质量检测方法 | |
CN107843657A (zh) | 通窍鼻炎片的质量检测方法 | |
CN104042824B (zh) | 一种治疗风寒湿邪中药组合物的制备方法及检测方法 | |
CN106822203B (zh) | 一种独活颗粒及其制备方法和质量控制方法 | |
CN106706774B (zh) | 面积归一化法测定西红花药材中西红花苷类成分的方法 | |
CN106501442A (zh) | 一种芩黄清肺散的质量检测方法 | |
CN114184696A (zh) | 一种宣肺败毒中药组合物的检测方法 | |
CN105301168B (zh) | 通络化痰胶囊的检测方法 | |
CN104502485B (zh) | 由穿山龙和刺五加为药材的中药复方制剂中6个化学成分的定量分析方法 | |
CN110320311A (zh) | 一种杜仲壮骨丸的质量检测方法 | |
CN102218122A (zh) | 一种海龙蛤蚧口服液的质量控制检测方法 | |
CN106153812A (zh) | 一种治疗子宫内膜异位症的中药制剂的检测方法 | |
CN106248860B (zh) | 一种儿脾醒颗粒的检测方法 | |
CN102879516B (zh) | 补阳还五汤的鉴别和含量测定方法 | |
CN108169403A (zh) | 一种八珍汤配方颗粒的质量检测方法 | |
CN105004833B (zh) | 一种治疗急性痛风性关节炎、痛风的中药制剂的检测方法 | |
CN105628851B (zh) | 一种中药制剂的检测方法 | |
CN106680414A (zh) | 一种复方矮地茶片的检测方法 | |
CN104345108B (zh) | 一种清肝片的定性定量检测方法 | |
CN106770882A (zh) | 一种含有人参或三七药材的中药制剂的检测方法 | |
CN103230448A (zh) | 一种黄连阿胶汤复方配方颗粒及其制备方法和检测方法 | |
CN108535399A (zh) | 一种妇炎康丸的检测方法 | |
CN106383194A (zh) | 风湿宁药酒中豨莶草的鉴别方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: 730300 No. 1739 Kunlunshan Avenue, Lanzhou New District, Lanzhou City, Gansu Province Applicant after: Gansu Lanyao Pharmaceutical Co., Ltd. Address before: 730046 Zhongbang Avenue, Anning District, Lanzhou City, Gansu Province Applicant before: Gansu Lanyao Pharmaceutical Co., Ltd. |
|
CB02 | Change of applicant information | ||
CB03 | Change of inventor or designer information |
Inventor after: Wang Zhifeng Inventor after: Yang Jun Inventor after: Lei Wengui Inventor after: Zhang Tao Inventor after: Su Haiyan Inventor after: Hou Hongxia Inventor before: Yang Jun Inventor before: Zhang Tao Inventor before: Wang Zhifeng Inventor before: Lei Wengui Inventor before: Hou Hongxia Inventor before: Su Haiyan |
|
CB03 | Change of inventor or designer information | ||
GR01 | Patent grant | ||
GR01 | Patent grant |